CSL Research Acceleration Initiative: Applications close 24th February 2026

APPLICATIONS CLOSE ON 24TH FEBRUARY 2026: Applications received outside these dates (before or after) will not be reviewed.

The CSL Research Acceleration Initiative supports early-stage biotechs and research organizations to fast-track the discovery of groundbreaking biotherapies.

Successful applicants can receive up to $400,000 USD in non-dilutive funding over 2 years to advance their innovative programs.

Focus Areas

CSL is seeking applications that align with a CSL Therapeutic Area in the following Focus Areas:

• Transplant & Immunology 
  Novel first in class targets and drug concepts to treat immune-mediated diseases
  Indication focus

• Cardiovascular & Renal
  Genetic rare renal diseases
  Autoimmune-mediated rare renal diseases
  Rare cardiovascular diseases

• Hematology
  Acute hemorrhage control and Patient Blood Management (PBM)
  Transformative therapies for Hemophilia A
  Iron metabolism
  Acute thrombotic conditions

• Immunoglobulins
  Patient Experience
  Novel Therapies
  Optimization of human-derived Ig products

• Oral Delivery

Interested researchers are invited to:

Attend an information webinar (choose one of two sessions)

Tuesday, 20 January 4:00PM CET (UTC+1) – Click to join

Tuesday, 3 February 11:00AM CET (UTC+1) – Click to join

Submit applications by 24th February here